Please login to the form below

Not currently logged in
Email:
Password:

Medicxi

This page shows the latest Medicxi news and features for those working in and with pharma, biotech and healthcare.

Novartis and J&J back latest €400m Medicxi biopharma fund

Novartis and J&J back latest €400m Medicxi biopharma fund

to Medicxi, with European companies growing in stature and offering improved returns on investment for backers. ... to the US, Medicxi’s co-founder Francesco De Rubertis told the Financial Times.

Latest news

More from news
Approximately 1 fully matching, plus 6 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest appointments

  • Medicxi appoints former GSK chair Moncef Slaoui Medicxi appoints former GSK chair Moncef Slaoui

    He joins the life science investment firm as a partner. London, UK-based life science investment group Medicxi has appointed former GSK chairman of pharmaceutical R&D, vaccines Dr Moncef Slaoui ... He said: “Having developed a strong relationship with

More from appointments
Approximately 1 fully matching, plus 0 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Nucleus Global

Nucleus Global is the largest specialist medical communications network in the world. Globally, we have over 800 experts delivering world-class...

Latest intelligence

How innovating study sites can improve patient recruitment efficiency
There are so many ways that clinical trials have innovated over the last few years. There is now a larger focus on making trials more patient-centric, more virtualised, and more...
PME-MAY21-Cover
Avoiding A Series of Unfortunate Events: launch lessons from lockdown
Chris Ross takes a novel look at launch excellence through the lens of COVID-19 and explores how pharma’s launch leaders are rewriting the story...
6 reasons patients drop out of clinical trials and 6 ways to fix it
If you’ve successfully recruited patients for your clinical trial, but one by one, they begin to drop out, then this information could be for you....